EE05210B1 - Suhkurt?vevastane preparaat ja selle kasutamine meditsiinis - Google Patents

Suhkurt?vevastane preparaat ja selle kasutamine meditsiinis

Info

Publication number
EE05210B1
EE05210B1 EEP200200241A EEP200200241A EE05210B1 EE 05210 B1 EE05210 B1 EE 05210B1 EE P200200241 A EEP200200241 A EE P200200241A EE P200200241 A EEP200200241 A EE P200200241A EE 05210 B1 EE05210 B1 EE 05210B1
Authority
EE
Estonia
Prior art keywords
medicine
antidiabetic agent
antidiabetic
agent
Prior art date
Application number
EEP200200241A
Other languages
English (en)
Inventor
Anne Piper Beth
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23716278&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE05210(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of EE200200241A publication Critical patent/EE200200241A/et
Publication of EE05210B1 publication Critical patent/EE05210B1/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
EEP200200241A 1999-11-03 2000-10-13 Suhkurt?vevastane preparaat ja selle kasutamine meditsiinis EE05210B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/432,465 US6586438B2 (en) 1999-11-03 1999-11-03 Antidiabetic formulation and method
PCT/US2000/028467 WO2001032158A2 (en) 1999-11-03 2000-10-13 Pharmaceutical composition comprising a combination of metformin and another antidiabetic agent

Publications (2)

Publication Number Publication Date
EE200200241A EE200200241A (et) 2003-12-15
EE05210B1 true EE05210B1 (et) 2009-10-15

Family

ID=23716278

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200241A EE05210B1 (et) 1999-11-03 2000-10-13 Suhkurt?vevastane preparaat ja selle kasutamine meditsiinis

Country Status (34)

Country Link
US (2) US6586438B2 (et)
EP (1) EP1253944A2 (et)
JP (2) JP2003529551A (et)
KR (2) KR100769786B1 (et)
CN (3) CN101273981B (et)
AR (1) AR026355A1 (et)
AU (1) AU781781B2 (et)
BG (2) BG106732A (et)
BR (1) BR0015295A (et)
CA (1) CA2389931A1 (et)
CZ (2) CZ304090B6 (et)
DE (1) DE60038455T2 (et)
EE (1) EE05210B1 (et)
ES (1) ES2302702T3 (et)
GE (2) GEP20053538B (et)
HK (1) HK1045655A1 (et)
HU (1) HUP0300642A3 (et)
IL (3) IL149138A0 (et)
LT (1) LT5025B (et)
LV (1) LV12907B (et)
MX (1) MXPA02004290A (et)
MY (2) MY136636A (et)
NO (1) NO20022086L (et)
NZ (1) NZ552074A (et)
PL (1) PL366112A1 (et)
RO (1) RO123109B1 (et)
RU (1) RU2276604C2 (et)
SK (1) SK4992002A3 (et)
TN (2) TNSN00207A1 (et)
TW (1) TWI241185B (et)
UA (2) UA76706C2 (et)
UY (1) UY26425A1 (et)
WO (1) WO2001032158A2 (et)
ZA (2) ZA200203368B (et)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235627B2 (en) * 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
US6414002B1 (en) * 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
US20030040469A1 (en) * 2000-03-08 2003-02-27 Knudsen Liselotte Bjerre Lowering serum lipids
AU2001241168B2 (en) * 2000-03-17 2005-06-16 Ajinomoto Co., Inc. Drugs for complications of diabetes and neuropathy and utilization thereof
FR2816840B1 (fr) 2000-11-17 2004-04-09 Flamel Tech Sa Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation
US7062312B2 (en) * 2001-01-17 2006-06-13 Pediamed Pharmaceuticals, Inc. Combination and method including a visual marker for determining compliance with a medication regimen
US20020187926A1 (en) * 2001-03-07 2002-12-12 Knudsen Liselotte Bjerre Combined use of derivatives of GLP-1 analogs and PPAR ligands
US20030022816A1 (en) * 2001-03-07 2003-01-30 Knudsen Liselotte Bjerre Combined use of derivatives of GLP-1 analogs and PPAR ligands
FR2825023B1 (fr) * 2001-05-23 2005-04-15 Flamel Tech Sa Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif
BR0213079A (pt) * 2001-09-28 2004-11-09 Sun Pharmaceutical Ind Ltd Forma de dosagem para o tratamento da diabetes mellitus
US6924311B2 (en) * 2001-10-17 2005-08-02 X-Ceptor Therapeutics, Inc. Methods for affecting various diseases utilizing LXR compounds
US7183321B2 (en) * 2001-12-17 2007-02-27 Bristol-Myers Squibb Company Antidiabetic formulation and method
ES2284829T3 (es) * 2002-01-25 2007-11-16 Laboratorios Silanes, S.A. De C.V. Composicion farmaceutica que se usa para controlar la glucosa en sangre en pacientes con diabetes de tipo 2.
CA2480826C (fr) 2002-04-09 2012-02-07 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
KR100897890B1 (ko) 2002-06-17 2009-05-18 인벤티아 헬스케어 피브이티. 엘티디. 티아졸리딘디온 및 바이구아나이드를 함유하는 다층 정제및 그의 제조 방법
AU2003243929B2 (en) * 2002-07-04 2009-06-04 Zp Holding Spv K/S GLP-1 and methods for treating diabetes
JP2004067575A (ja) * 2002-08-06 2004-03-04 Yaizu Suisankagaku Industry Co Ltd 糖尿病治療薬効果促進剤
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
SE526943C2 (sv) * 2002-08-26 2005-11-22 Indevex Ab Födoämneskompositionsprodukt
UA80991C2 (en) 2002-10-07 2007-11-26 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
US20040147564A1 (en) * 2003-01-29 2004-07-29 Rao Vinay U. Combinations of glimepiride and the thiazolidinedione for treatment of diabetes
CA2536111A1 (en) * 2003-07-24 2005-02-03 Wockhardt Limited Oral compositions for treatment of diseases
SI1648933T1 (sl) * 2003-07-25 2010-01-29 Conjuchem Biotechnologies Inc Dolgo delujoäś inzulinski derivat in metoda zanj
US20050202063A1 (en) * 2003-08-26 2005-09-15 Ebn International Kft Food product
US20050163842A1 (en) * 2003-12-31 2005-07-28 Garth Boehm Rosiglitazone and metformin formulations
WO2005065654A2 (en) * 2003-12-31 2005-07-21 Alpharma, Inc. Rosiglitazone formulations
WO2005107750A1 (en) * 2004-04-29 2005-11-17 Andrx Labs. Llc Controlled release metformin compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
US20060188590A1 (en) * 2005-01-05 2006-08-24 Mitsunori Ono Compositions for treating diabetes or obesity
KR20070102694A (ko) * 2005-01-31 2007-10-19 아지노모토 가부시키가이샤 혈당 강하제를 함유하는, 내당능 이상, 경계형 당뇨병,인슐린 저항성 및 고인슐린혈증 개선 또는 치료용 의약조성물
EP1889618A4 (en) * 2005-05-27 2010-11-24 Daiichi Sankyo Co Ltd COMBINED MEDICINE FOR THE TREATMENT OF DIABETES
BRPI0620718A2 (pt) * 2005-10-28 2011-11-22 Takeda Pharmaceutical agente para a proteção do páncreas, e, uso de uma droga para a redução de glicose
WO2007070355A2 (en) * 2005-12-09 2007-06-21 Metaproteomics, Llc Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes
FR2896157B1 (fr) * 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.
NO347644B1 (no) 2006-05-04 2024-02-12 Boehringer Ingelheim Int Polymorfer
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
EP2051732A4 (en) * 2006-07-26 2009-10-21 Diamedica Inc DIAGNOSIS AND TREATMENT OF METABOLIC DISORDERS AND METHODS THEREFOR
AR071175A1 (es) 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
US20100136561A1 (en) * 2008-05-16 2010-06-03 Interleukin Genetics, Inc. Genetic Markers for Weight Management and Methods of Use Thereof
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
KR101189639B1 (ko) * 2008-12-15 2012-10-12 씨제이제일제당 (주) 메트포르민 및 α-글리코시다제 억제제를 포함하는 경구 제제 및 그 제조방법
EP3222277B1 (en) 2009-03-31 2020-02-26 Ligand Pharmaceuticals Inc. A biphenylsulfonamide endothelin and angiotensin ii receptor antagonist to treat glomerulosclerosis and iga-induced nephropathy
RU2538691C2 (ru) 2009-04-29 2015-01-10 Амарин Фарма, Инк. Стабильные фармацевтические композиции и способы их применения
EP3563842A1 (en) 2009-04-29 2019-11-06 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
LT3318255T (lt) 2009-06-15 2021-05-25 Amarin Pharmaceuticals Ireland Limited Kompozicijos ir būdai, skirti insulto gydymui pacientui kartu su statinų terapija
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
AU2010323068B2 (en) 2009-11-27 2015-09-03 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
CN101810628B (zh) * 2010-04-13 2012-05-23 北京四环科宝制药有限公司 二甲双胍格列吡嗪片及其制备方法
SG184988A1 (en) 2010-04-27 2012-11-29 Zealand Pharma As Peptide conjugates of glp-1 receptor agonists and gastrin and their use
WO2011138421A1 (en) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy
HUE029853T2 (en) 2010-05-11 2017-04-28 Janssen Pharmaceutica Nv Pharmaceutical formulations containing 1- (beta-D-Glucopyranosyl) -2-thienylmethylbenzene derivatives as SGLT inhibitors
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
NZ744990A (en) 2010-11-29 2019-10-25 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
WO2012090225A2 (en) * 2010-12-29 2012-07-05 Nutracryst Therapeutics Private Limited Novel cocrystals / molecular salts of metformin with oleoylethanolamide as an effective anti-diabetic + anti- obesity agent
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
SG10201607085WA (en) 2011-01-07 2016-10-28 Elcelyx Therapeutics Inc Chemosensory Receptor Ligand-Based Therapies
US9480663B2 (en) 2011-01-07 2016-11-01 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
US8796338B2 (en) 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
US9572784B2 (en) 2011-01-07 2017-02-21 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
KR20140100947A (ko) 2011-11-03 2014-08-18 질랜드 파마 에이/에스 Ｇｌｐ-1 수용체 효능제 펩타이드 가스트린 접합체들
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
JP6175074B2 (ja) 2012-01-06 2017-08-02 エルセリクス セラピューティクス インコーポレイテッド 代謝障害を治療するための組成物および方法
BR112014016808B1 (pt) 2012-01-06 2022-01-11 Anji Pharma (Us) Llc Uso de um composto de biguanida para a fabricação de um medicamento para baixar os níveis de glicose no sangue e para o tratamento de um distúrbio do metabolismo de glicose
WO2013115742A1 (en) * 2012-01-31 2013-08-08 Mahmut Bilgic Pharmaceutical composition comprising alpha-glucosidase inhibitor
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US20130315891A1 (en) 2012-05-25 2013-11-28 Matthew Charles Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
CA2880085C (en) 2012-06-04 2021-09-07 Diamedica Inc. Human tissue kallikrein 1 glycosylation isoforms
CA2878991C (en) 2012-07-23 2021-12-07 Zealand Pharma A/S Glucagon analogues
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
KR101336499B1 (ko) * 2013-03-06 2013-12-03 씨제이제일제당 (주) 당뇨병의 예방 또는 치료용 복합 조성물
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
US9896495B2 (en) 2013-10-17 2018-02-20 Zealand Pharma A/S Acylated glucagon analogues
KR102310392B1 (ko) 2013-11-06 2021-10-13 질랜드 파마 에이/에스 글루카곤-ｇｌｐ-1-ｇｉｐ 삼원 효능제 화합물
JP6682432B2 (ja) 2013-11-06 2020-04-15 ジーランド ファーマ アクティーゼルスカブ Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法
WO2015128453A1 (en) 2014-02-28 2015-09-03 Boehringer Ingelheim International Gmbh Medical use of a dpp-4 inhibitor
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
WO2016066744A2 (en) 2014-10-29 2016-05-06 Zealand Pharma A/S Gip agonist compounds and methods
KR20170137198A (ko) 2015-04-16 2017-12-12 질랜드 파마 에이/에스 아실화된 글루카곤 유사체
US10155000B2 (en) 2016-06-10 2018-12-18 Boehringer Ingelheim International Gmbh Medical use of pharmaceutical combination or composition
MX2019006486A (es) 2016-12-09 2019-08-01 Zealand Pharma As Agonistas duales acilados de glp-1/glp-2.
WO2018165551A1 (en) 2017-03-09 2018-09-13 Diamedica Inc. Dosage forms of tissue kallikrein 1
CN113677355A (zh) * 2018-09-24 2021-11-19 潘德勒姆治疗公司 微生物组合物及使用方法
FI4056176T3 (fi) 2018-09-24 2024-05-30 Amarin Pharmaceuticals Ie Ltd Menetelmät kardiovaskulaaristen tapahtumien riskin pienentämiseksi tutkittavassa
CN113648318B (zh) * 2020-05-12 2023-08-25 中国科学院上海营养与健康研究所 增强细胞产热和治疗疾病的应用
AU2022263358A1 (en) 2021-04-21 2023-11-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
DE2348334C2 (de) 1973-09-26 1982-11-11 Boehringer Mannheim Gmbh, 6800 Mannheim Neue Zubereitungsform des N-4-[2-(5-Chlor-2-methoxybenzamido)äthyl]- phenyl-sulfonyl-N'-cyclohexylharnstoffs
US4060634A (en) 1973-09-26 1977-11-29 Boehringer Mannheim G.M.B.H. Rapidly resorbable glibenclamide
NO154918C (no) 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
EP0062704A1 (de) 1980-12-03 1982-10-20 Hoechst Aktiengesellschaft Cyclopropancarbonsäureester-derivate als Mittel zum Bekämpfen von Magendasseln bei Equiden
JPS6051189A (ja) 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
US4916163A (en) 1985-06-04 1990-04-10 The Upjohn Company Spray-dried lactose formulation of micronized glyburide
DE3543999A1 (de) 1985-12-13 1987-06-19 Bayer Ag Hochreine acarbose
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
DE3833439A1 (de) 1988-10-01 1991-09-12 Hoechst Ag Verfahren zur mikronisierung von glibenclamid
US5258185A (en) * 1989-08-23 1993-11-02 Bauer Kurt H Highly active, rapidly absorbable formulations of glibenclamide, processes for the production thereof and their use
DK36392D0 (da) 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
DE4323636A1 (de) 1993-07-15 1995-01-19 Hoechst Ag Arzneistoffzubereitungen aus umhüllten, schwerstwasserlöslichen Arzneistoffen für Inhalationsarzneiformen und Verfahren zu ihrer Herstellung
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
IT1276130B1 (it) 1995-11-14 1997-10-27 Gentili Ist Spa Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
US6153632A (en) 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
JP4083818B2 (ja) * 1997-06-06 2008-04-30 ディポメド，インコーポレイティド 高度可溶性薬物の制御された放出のための胃滞留性の経口薬物投与形
DK1011673T3 (da) 1997-06-13 2001-07-09 Novo Nordisk As Hidtil ukendt metode til behandling af nidom
AU8539398A (en) 1997-06-18 1999-01-04 Smithkline Beecham Plc Treatment of diabetes with thiazolidinedione and metformin
GB9715306D0 (en) 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
EP1030665A4 (en) 1997-10-17 2002-11-27 Aventis Pharm Prod Inc THERAPEUTIC USE OF CHINOLINE DERIVATIVES
JP4278863B2 (ja) 1997-12-08 2009-06-17 ブリストル−マイヤーズ スクイブ カンパニー メトホルミンの新規塩および方法
FR2774591B1 (fr) 1998-02-12 2000-05-05 Lipha Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie
FI111167B (fi) * 1998-02-24 2003-06-13 Kemira Chemicals Oy Menetelmä lietteen säilyvyyden parantamiseksi
EP1056774A1 (en) 1998-02-27 2000-12-06 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
DE69818444T2 (de) 1998-07-15 2004-05-06 Merck Santé Tabletten enthaltend eine Kombination von Glibenclamid und Metformin
WO2000015229A1 (en) 1998-09-17 2000-03-23 Bristol-Myers Squibb Company METHOD FOR TREATING DIABETES EMPLOYING AN aP2 INHIBITOR AND COMBINATION
AR028299A1 (es) 1999-09-17 2003-05-07 Novartis Ag Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes.
EP2620443A1 (en) 2012-01-25 2013-07-31 Galecto Biotech AB Novel galactoside inhibitors of galectins

Also Published As

Publication number Publication date
KR100769786B1 (ko) 2007-10-24
JP2003529551A (ja) 2003-10-07
AU8022900A (en) 2001-05-14
EP1253944A2 (en) 2002-11-06
KR20020050253A (ko) 2002-06-26
GEP20053539B (en) 2005-06-10
US20020177602A1 (en) 2002-11-28
HUP0300642A3 (en) 2006-05-29
IL149138A0 (en) 2002-11-10
LT2002062A (en) 2003-03-25
CA2389931A1 (en) 2001-05-10
TNSN00206A1 (en) 2005-11-10
LV12907B (en) 2003-08-20
MY136636A (en) 2008-11-28
US6586438B2 (en) 2003-07-01
UA75583C2 (uk) 2006-05-15
RU2002113764A (ru) 2004-03-20
CN101273981B (zh) 2011-01-26
CN101273981A (zh) 2008-10-01
BG65850B1 (bg) 2010-03-31
TNSN00207A1 (en) 2005-11-10
MXPA02004290A (es) 2003-02-12
PL366112A1 (en) 2005-01-24
BG106732A (bg) 2003-02-28
JP2013028631A (ja) 2013-02-07
WO2001032158A3 (en) 2002-08-29
EE200200241A (et) 2003-12-15
SK4992002A3 (en) 2003-04-01
ZA200203367B (en) 2003-09-10
LT5025B (lt) 2003-06-25
GEP20053538B (en) 2005-06-10
DE60038455T2 (de) 2009-04-23
US7598262B2 (en) 2009-10-06
CZ304090B6 (cs) 2013-10-16
IL149139A (en) 2011-11-30
TWI241185B (en) 2005-10-11
BG106733A (bg) 2003-02-28
MY125118A (en) 2006-07-31
ZA200203368B (en) 2003-09-02
AU781781B2 (en) 2005-06-16
HUP0300642A2 (hu) 2003-07-28
CZ20021547A3 (cs) 2003-01-15
NZ552074A (en) 2008-06-30
US20020183345A1 (en) 2002-12-05
CN100386114C (zh) 2008-05-07
WO2001032158A2 (en) 2001-05-10
RU2276604C2 (ru) 2006-05-20
KR20020057994A (ko) 2002-07-12
AR026355A1 (es) 2003-02-05
HK1045655A1 (zh) 2002-12-06
DE60038455D1 (de) 2008-05-08
UA76706C2 (uk) 2006-09-15
NO20022086D0 (no) 2002-05-02
RO123109B1 (ro) 2010-11-30
IL149138A (en) 2007-12-03
BR0015295A (pt) 2003-06-24
ES2302702T3 (es) 2008-08-01
CN1414862A (zh) 2003-04-30
CN102283853A (zh) 2011-12-21
UY26425A1 (es) 2001-07-31
NO20022086L (no) 2002-06-24

Similar Documents

Publication Publication Date Title
EE05210B1 (et) Suhkurt?vevastane preparaat ja selle kasutamine meditsiinis
EE04452B1 (et) Farmatseutiliselt aktiivne morfolinool ja selle kasutamine
EE04144B1 (et) Farmatseutiline kompositsioon ja selle kasutamine
EE200200341A (et) Asendatud oksasolidinoonid ja nende kasutamine
IL156678A0 (en) Glucopyranosyloxypyrazole derivatives and use thereof in medicines
ID26340A (id) Kapsul ganda dengan penggunaan bahan-bahan aktif dalam berbagai macam pengobatan
EE200100568A (et) 6-alkenüül-, 6-alkünüül- ja 6-epoksüepotilooni derivaadid, nende valmistamismeetod ja kasutamine farmatseutilistes preparaatides
EE04879B1 (et) Sünteetilised pindaktiivsed peptiidid ja nende kasutamine sünteetilise surfaktandi valmistamiseks
EE05067B1 (et) Aminoproplfosfiinhapped ning nende kasutamine meditsiinis
EE04565B1 (et) Adamantaani derivaadid, nende saamine ja kasutamine
AU2002225356A1 (en) Glucopyranosyloxypyrazole derivatives and use thereof in medicines
ID22565A (id) Penggunaan nanodispersi dalam formulasi akhir obat
EE200200414A (et) Dihüdro-1,3,5-triasiinamino derivaadid ja nende kasutamine ravis
EE200200484A (et) Väikeseannuseline entekaviiripreparaat ja selle kasutamine
EE200100391A (et) Peptidüül-heterotsüklilised ketoonid, nende kasutamine ja farmatseutiline kompositsioon
PT1212317E (pt) Derivados de indole e sua utilizacao no tratamento de osteoporose entre outras aplicacoes
EE05000B1 (et) 2'-asendatud 1,1'-bifenüül-2-karboksamiidid, nende kasutamine ja farmatseutilised preparaadid
DE60022828D1 (de) Kosmetikeinheit und deren Zusammensetzung
FI20000818A0 (fi) Dermatologinen käyttö ja valmiste
EE9900524A (et) N-triasolüül-2-indoolkarboksamiidid ja nende kasutamine CCK-A agonistidena
EE03667B1 (et) Alfa -2 - adrenotseptori antagonisti, selle derivaadi kasutamine ravimi valmistamiseks vaimuhaiguseravimiseks imetajatel ja kompositsioon selle tarvis
EE9900135A (et) N-(2-bensotiasolüül)-1-piperidiinetaanamiini derivaadid, nende valmistamine ja kasutamine raviks
EE200000712A (et) Eeltäidetud süstal ja selle kasutamine
EE200100363A (et) ((Aminoiminometüül)amino)alkaankarboksamiidid ja nende kasutamine ravis
EE200200168A (et) PRV-1-geen ja selle kasutamine

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20131013